Avadel Pharmaceuticals Retained Earnings Over Time
| AVDL Stock | USD 11.22 0.44 3.77% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Avadel Pharmaceuticals Performance and Avadel Pharmaceuticals Correlation. Avadel |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avadel Pharmaceuticals. If investors know Avadel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avadel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.09) | Revenue Per Share 1.036 | Quarterly Revenue Growth 26.743 | Return On Assets (0.34) | Return On Equity (1.00) |
The market value of Avadel Pharmaceuticals is measured differently than its book value, which is the value of Avadel that is recorded on the company's balance sheet. Investors also form their own opinion of Avadel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Avadel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avadel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Avadel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Avadel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Avadel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avadel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Retained Earnings Analysis
Compare Avadel Pharmaceuticals and related stocks such as Capricor Therapeutics, Soleno Therapeutics, and Bio Path Holdings Retained Earnings Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CAPR | (717) | (44.8 M) | (46.7 M) | (16.1 M) | (22.3 M) | (35.2 M) | (54 M) | (51.5 M) | (66.7 M) | (74.4 M) | (88 M) | (108.1 M) | (137.1 M) | (159.4 M) | (151.4 M) |
| SLNO | (53.4 M) | (53.4 M) | (53.4 M) | (57.1 M) | (71 M) | (86.2 M) | (98.3 M) | (114 M) | (127 M) | (157.8 M) | (182.4 M) | (213.4 M) | (237.4 M) | (276.4 M) | (262.6 M) |
| BPTH | (288.1 K) | (9.5 M) | (12.1 M) | (15.4 M) | (19.9 M) | (25.4 M) | (32.1 M) | (39.2 M) | (47.7 M) | (56.3 M) | (67.2 M) | (77.7 M) | (91.5 M) | (107.6 M) | (102.2 M) |
| MBRX | (748.4 K) | (748.4 K) | (748.4 K) | (748.4 K) | (748.4 K) | (748.4 K) | (4.7 M) | (14.5 M) | (26.4 M) | (39.6 M) | (56.9 M) | (72.8 M) | (101.8 M) | (131.6 M) | (125 M) |
| CRNX | (7.1 M) | (7.1 M) | (7.1 M) | (7.1 M) | (7.1 M) | (7.1 M) | (7.1 M) | (16.3 M) | (43.4 M) | (93.8 M) | (167.6 M) | (275.3 M) | (439.2 M) | (653.7 M) | (621 M) |
| ASMB | (13.4 M) | (67.5 M) | (92.3 M) | (111.7 M) | (135.5 M) | (164 M) | (208.2 M) | (251 M) | (341.8 M) | (439.4 M) | (501.6 M) | (631.4 M) | (724.5 M) | (785.7 M) | (746.5 M) |
| TIL | (7.2 M) | (7.2 M) | (7.2 M) | (7.2 M) | (7.2 M) | (7.2 M) | (7.2 M) | (7.2 M) | (7.2 M) | (7.2 M) | (44.9 M) | (201.7 M) | (424.9 M) | (581 M) | (551.9 M) |
| CTMX | (43.9 M) | (43.9 M) | (43.9 M) | (43.9 M) | (78.1 M) | (117.5 M) | (176.4 M) | (219.5 M) | (315 M) | (417.2 M) | (450.1 M) | (533.7 M) | (722.9 M) | (723.4 M) | (687.3 M) |
| ACHL | (10.8 M) | (10.8 M) | (10.8 M) | (10.8 M) | (10.8 M) | (10.8 M) | (10.8 M) | (10.8 M) | (10.8 M) | (24.8 M) | (58 M) | (119.1 M) | (190.3 M) | (260 M) | (247 M) |
Avadel Pharmaceuticals and related stocks such as Capricor Therapeutics, Soleno Therapeutics, and Bio Path Holdings Retained Earnings description
The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.My Equities
My Current Equities and Potential Positions
| Avadel Pharmaceuticals PLC | AVDL |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Ireland |
| Exchange | NASDAQ Exchange |
USD 11.22
Check out Avadel Pharmaceuticals Performance and Avadel Pharmaceuticals Correlation. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Avadel Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.